In addition, the study [88] demonstrated that patients treated with DMARDs and TNFα inhibitors had lower ATM levels than other RA patients, which indicates that these medications might modulate the immune response and inflammation in adipose tissue of RA patients. The gene discussed is ATM; the disease is rheumatoid arthritis.